What is the ideal study design for evaluation of treatment for heart failure?: Insights from trials assessing the effect of ACE inhibitors on exercise capacity
Why the study?
How do study design factors affect the ability to detect improvements in exercise capacity and symptoms with ACE inhibitors in patients with symptomatic chronic heart failure?
Population
35 published, double-blind, randomized placebo-controlled trials involving a total of 3411 patients with…
Comparison
ACE inhibitors vs Placebo
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Well-designed trials (n>50, 3-6 months, treadmill) detect ACE inhibitor benefits on exercise capacity and symptoms in HF; confirms study design as key to revealing treatment effects.
Key Points
- To determine how trial design and methodology influence the detection of improvements in symptoms and exercise capacity among patients with chronic heart failure receiving ACE inhibitors.
- Reviewed 35 published, double-blind, randomized placebo-controlled trials encompassing 3,411 patients with symptomatic chronic heart failure evaluating ACE inhibitors versus placebo.
- Analyzed trial characteristics including cross-over versus parallel design, sample size, exercise modality (treadmill vs. bicycle ergometry), publication year, inclusion criteria, follow-up duration, and specific ACE inhibitor agent.
- Exercise duration improved in 23 of 35 trials, while symptoms improved in 25 of 33 trials evaluating symptomatic outcomes.
- Concordance between symptom improvement and exercise capacity was present in 27 of 33 trials, while 6 trials demonstrated discrepant results.
- Study size, follow-up duration, and exercise test modality significantly influenced outcomes; all 9 trials with sample sizes over 50, follow-up of 3–6 months, and treadmill exercise testing demonstrated improvements in both exercise capacity and symptoms.
Structured PICO
How do study design factors affect the ability to detect improvements in exercise capacity and symptoms with ACE inhibitors in patients with symptomatic chronic heart failure?
P
Population
35 published, double-blind, randomized placebo-controlled trials involving a total of 3411 patients with symptomatic chronic heart failure
I
Intervention
ACE inhibitors
C
Comparator
Placebo
O
Outcome
Exercise capacity and symptomssurrogate
Study size, duration of follow-up, and method of exercise testing (treadmill vs bicycle) are major factors affecting the ability to detect treatment benefits in heart failure trials.
Cite This Study
Narang et al. (1996) studied this question.